New partnership with Bora. Read more

New Scientific Publication: Advancing Oral Delivery Strategies for Intestinal Inflammation

News

New Scientific Publication: Advancing Oral Delivery Strategies for Intestinal Inflammation

Corealis Pharma is proud to highlight a new collaborative scientific publication co-authored by Patrick Gosselin, VP R&D, exploring innovative oral dosage forms designed to protect and deliver catalase and probiotics for potential applications in intestinal inflammation.

Oral Dosage Forms of Catalase Associated with Probiotics Using Carboxymethylcellulose and Carboxymethylstarch: A Potential Approach for Intestinal Inflammation

Authors: Al Hadji Malick Dieye, Patrick Gosselin, Armelle Tchoumi Neree, Younès Chorfi, and Mircea Alexandru Mateescu.

Journal: International Journal of Molecular Sciences, 2026, 27(22), 10358. Published November 18, 2026.

Abstract

This study investigates innovative oral tablet formulations using carboxymethylcellulose (CMC) and carboxymethylstarch (CMS) to protect catalase, an antioxidant enzyme, during gastrointestinal transit. Under simulated gastrointestinal conditions, the formulations preserved catalase activity and demonstrated effective hydrogen peroxide degradation, while co-formulation with probiotics maintained bacterial viability. These promising in vitro findings highlight the potential of combining antioxidant enzymes and probiotics in oral dosage forms to address intestinal oxidative stress and microbiota imbalance. The research contributes to ongoing advances in oral drug delivery and formulation technologies for complex bioactive compounds.